« Previous Next » Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 33-37 , January 2012

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results

Renee C. Prins, M.D.
- Division of Hematology and Medical Oncology, Oregon Health and Science University (Sam Jackson Park Rd.), Portland, OR 97239, USA
Brooks L. Rademacher, B.A.
- OHSU Knight Cancer Institute, Oregon Health and Science University (Bond Ave.), Portland, OR 97239, USA
Solange Mongoue-Tchokote, M.S.
- OHSU Knight Cancer Institute, Oregon Health and Science University (Sam Jackson Park Rd.), Portland, OR 97239, USA
Joshi J. Alumkal, M.D.
- OHSU Knight Cancer Institute, Oregon Health and Science University (Bond Ave.), Portland, OR 97239, USA
Julie N. Graff, M.D.
- OHSU Knight Cancer Institute, Oregon Health and Science University (Bond Ave.), Portland, OR 97239, USA
Kristine M. Eilers, B.A.
- OHSU Knight Cancer Institute, Oregon Health and Science University (Bond Ave.), Portland, OR 97239, USA
Tomasz M. Beer, M.D.
- OHSU Knight Cancer Institute, Oregon Health and Science University (Bond Ave.), Portland, OR 97239, USA
- Corresponding author. Tel.: +1-503-494-0365; fax: +1-503-494-6197

Received 6 October 2009 ,Revised 10 November 2009 ,Accepted 10 November 2009.

Kaplan-Meier curve of below the median (≤5 mg/L) or above the median (>5 mg/l) C-reactive protein (CRP) on overall survival in men with castrate-resistant prostate cancer (log rank P < 0.0001). (Color

Kaplan-Meier curve of below the median (≤5 mg/L) or above the median (>5 mg/l) C-reactive protein (CRP) on overall survival in men with castrate-resistant prostate cancer (log rank P < 0.0001). (Color version of figure is available online.)
- Full-Size Image
- Download to PowerPoint